BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18067883)

  • 41. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
    Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
    Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lysosomal cysteine proteases and antigen presentation.
    Rudensky A; Beers C
    Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection.
    Martin WD; Hicks GG; Mendiratta SK; Leva HI; Ruley HE; Van Kaer L
    Cell; 1996 Feb; 84(4):543-50. PubMed ID: 8598041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
    Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
    J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Class II MHC peptide loading by the professionals.
    Bryant P; Ploegh H
    Curr Opin Immunol; 2004 Feb; 16(1):96-102. PubMed ID: 14734116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
    Moldenhauer G; Henne C; Karhausen J; Möller P
    Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MHC class II molecules on the move for successful antigen presentation.
    Rocha N; Neefjes J
    EMBO J; 2008 Jan; 27(1):1-5. PubMed ID: 18046453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptide-specific intercellular transfer of MHC class II to CD4+ T cells directly from the immunological synapse upon cellular dissociation.
    Wetzel SA; McKeithan TW; Parker DC
    J Immunol; 2005 Jan; 174(1):80-9. PubMed ID: 15611230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
    Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells.
    Karlsson L; Péléraux A; Lindstedt R; Liljedahl M; Peterson PA
    Science; 1994 Dec; 266(5190):1569-73. PubMed ID: 7985028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
    Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
    Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells.
    Tobian AA; Canaday DH; Harding CV
    J Immunol; 2004 Oct; 173(8):5130-7. PubMed ID: 15470057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The bio-logical role of invariant chain (Ii) in MHC class II antigen presentation.
    Nordeng TW; Bakke O
    Immunol Lett; 1994 Dec; 43(1-2):47-55. PubMed ID: 7737689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo.
    Ghumman B; Bertram EM; Watts TH
    J Immunol; 1998 Oct; 161(7):3262-70. PubMed ID: 9759841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
    Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
    J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
    Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
    Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors.
    Wubbolts R; Neefjes J
    Immunol Rev; 1999 Dec; 172():189-208. PubMed ID: 10631947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain.
    Rajagopalan G; Smart MK; Krco CJ; David CS
    J Immunol; 2002 Aug; 169(4):1774-83. PubMed ID: 12165499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
    Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
    J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.